[ad_1]
BioNTech and Pfizer confirmed on Wednesday that they have reached an agreement for the European Commission to purchase up to 300 million doses of their flagship vaccine against the coronavirus.
“As a company founded in the heart of Europe, we look forward to supplying millions of people after regulatory approval,” BioNTech co-founder Ugur Sahin wrote in a statement.
The Commission has agreed to purchase 200 million doses of the vaccine, with the possibility of purchasing an additional 100 million, according to a press release from the company.
Pfizer CEO Albert Bourla said it was “the largest initial order for vaccine doses … to date” for companies.
The vaccine will be manufactured both at the Belgian production sites of Pfizer and BioNTech in Germany. The company hopes to manufacture 1.3 billion doses in 2021.
The companies announced Monday that their vaccine was 90% effective and could submit data to the European Medicines Agency as early as next week.
Some worried after the news that the EU had not yet completed its contract for vaccines, unlike the United States and the United Kingdom.
The Commission was quick on Monday to point out that the deal would be concluded soon.
The Commission completed “exploratory discussions” with BioNTech and Pfizer in September. The Commission has completed similar discussions with two other vaccine producers and signed agreements with three others, including another AstraZeneca favorite.
[ad_2]
Source link